Literature DB >> 3010952

Modulation of cyclic AMP action in the dog thyroid by its agonist and antagonist Sp- and Rp-adenosine 3',5'-monophosphorothioate.

C Erneux, J Van Sande, B Jastorff, J E Dumont.   

Abstract

The diastereoisomeric forms of adenosine 3',5'-monophosphorothioate, Sp-cAMPS and Rp-cAMPS, have been shown to mimic and to inhibit activation of protein kinase type I and type II by cyclic AMP. In the present work, Sp-cAMPS mimicked thyrotropin (TSH) action on thyroid hormone secretion and protein iodination in dog thyroid slices, whereas Rp-cAMPS antagonized those effects. The phosphorothioates have been tested as inhibitors or activators of the three major phosphodiesterases: the Ca2+/calmodulin-sensitive form, the cyclic GMP-stimulated form and the cyclic AMP-specific enzyme. At 100 microM Sp-cAMPS inhibited the three enzyme activities. In contrast, Rp-cAMPS failed to stimulate activity of the three enzymes. From a comparison of the biological properties of Sp- and Rp-cAMPS and 3-isobutyl-1-methyl xanthine, it is suggested that one site of action of the phosphorothioates is on the cyclic AMP-dependent protein kinases, i.e. the effects of Sp-cAMPS and Rp-cAMPS observed in intact cell can be ascribed to the agonistic and antagonistic effects on the cyclic AMP-dependent protein kinases. However, partial inhibition of phosphodiesterase activities by the phosphorothioates cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3010952      PMCID: PMC1146544          DOI: 10.1042/bj2340193

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  18 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Characterization of horse thyroid cyclic nucleotide phosphodiesterases.

Authors:  C Erneux; D Couchie; J E Dumont
Journal:  Eur J Biochem       Date:  1980-02

Review 3.  Cyclic nucleotide phosphodiesterases.

Authors:  J N Wells; J G Hardman
Journal:  Adv Cyclic Nucleotide Res       Date:  1977

Review 4.  The action of thyrotropin on thyroid metabolism.

Authors:  J E Dumont
Journal:  Vitam Horm       Date:  1971       Impact factor: 3.421

5.  Stimulation of thyroid metabolism by thyrotropin, cyclic 3':5'-AMP, dibutyryl cyclic 3':5'-AMP and prostaglandin E1.

Authors:  F Rodesch; P Neve; C Willems; J E Dumont
Journal:  Eur J Biochem       Date:  1969-03

6.  In vitro nonbutanol-extractable iodine release in dog thyroid.

Authors:  J Unger; J M Boeynaems; A Van Herle; J Van Sande; P Rocmans; J Mockel
Journal:  Endocrinology       Date:  1979-07       Impact factor: 4.736

7.  The involvement of a calmodulin-dependent phosphodiesterase in the negative control of carbamylcholine on cyclic AMP levels in dog thyroid slices.

Authors:  F Miot; J E Dumont; C Erneux
Journal:  FEBS Lett       Date:  1983-01-24       Impact factor: 4.124

8.  Interaction of cAMP derivatives with the 'stable' cAMP-binding site in the cAMP-dependent protein kinase type I.

Authors:  R J de Wit; J Hoppe; W J Stec; J Baraniak; B Jastorff
Journal:  Eur J Biochem       Date:  1982-02

9.  Dissociation by cooling of hormone and cholera toxin activation of adenylate cyclase in intact cells.

Authors:  J van Sande; R Pochet; J E Dumont
Journal:  Biochim Biophys Acta       Date:  1979-06-12

10.  Forskolin stimulates adenylate cyclase and iodine metabolism in thyroid.

Authors:  J van Sande; P Cochaux; J E Dumont
Journal:  FEBS Lett       Date:  1982-12-13       Impact factor: 4.124

View more
  2 in total

1.  On the mechanism of histamine induced enhancement of the cardiac Ca2+ current.

Authors:  J Hescheler; M Tang; B Jastorff; W Trautwein
Journal:  Pflugers Arch       Date:  1987-09       Impact factor: 3.657

2.  Protein kinase A and nicotinic activation of bovine adrenal tyrosine hydroxylase.

Authors:  P D Marley; K A Thomson; R A Bralow
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.